Iptacopan in IgA Nephropathy — Final 24-Month Data

20260 citationsJournal Article

Authors

Jonathan Barratt · University of Leicester

Necmi Eren · Kocaeli Üniversitesi

Naoki Kashihara · Kawasaki Medical School

Bart Maes · AZ Delta

Dana V. Rizk · University of Alabama at Birmingham

Brad Rovin · The Ohio State University Wexner Medical Center

Hernán Trimarchi ·

Abstract

Iptacopan therapy led to a significantly slower decline in kidney function than placebo. (Funded by Novartis; APPLAUSE-IgAN ClinicalTrials.gov number, NCT04578834.).

Topics & Keywords

Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments Chronic Kidney Disease and Diabetes

Publication Details

Published in: New England Journal of Medicine

DOI: 10.1056/nejmoa2600743

Field-Weighted Citation Impact: 0.00

Command Palette

Iptacopan in IgA Nephropathy — Final 24-Month Data

Authors

Abstract

Topics & Keywords

Publication Details